Skip to main content
L

Not yet reviewed: this article is pending editorial review by Lyrea.

Citation noticeOur citation system is being overhauled

References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.

4-HO-MPMI

This article is a stubmissing:
Subjective Effects
Interactions
Tolerance
Legality
4-HO-MPMI molecule structure4-HO-MPMI molecule structure
Open in Piru
Chemical Class
Tryptamine

4-HO-MPMI is a psychedelic in the pyrrolidinylmethylindole and cyclized tryptamine families. It was developed in the late 1990s by a team led by David E. Nichols at Purdue University. Its psychedelic effects are described as similar to those of other psychoactive tryptamines, and its potency is reported to be comparable to DOI.

Dosage & Duration

Log in Piru

Dosage

Doses are population estimates that vary widely between individuals.

Threshold500-750 µg
Moderate1-2 mg

Limited dosing data exists for this compound, with no documented reports exceeding 2 mg. The potency appears comparable to DOI. Exercise considerable caution when determining doses.

Duration

Onset15-60 minutes
Total6-8 hours

Subjective Effects

Subjective Effects not written up yet

Pharmacology

Pharmacodynamics

4-HO-MPMI binds to the serotonin 5-HT2A receptor with a Ki of 13 nM. In drug discrimination assays in LSD- and DOI-trained rats, its (R)-enantiomer produces hallucinogen-like behavioral responses at a potency comparable to DOI.1 Of its two enantiomers, the (R)-enantiomer is active in rat drug discrimination assays.1

Pharmacokinetics

Absorption & half-lifenot documented yetMetabolitesnone documented yet

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check TripSit

Tolerance

Tolerance not written up yet

Harm Potential

Toxicity

Lethal Dosage

Reported dose information does not identify use above 2 mg, so dosing should be approached cautiously; no toxic or lethal dose is provided.

thermoregulatory/autonomic

Sweating and chills are listed among negative effects.

musculoskeletal

Muscle tension is listed among negative effects.

central nervous system

Confusion and insomnia are listed among negative effects.

History & Culture

4-HO-MPMI was developed in the late 1990s by a team led by David E. Nichols at Purdue University. Also known as lucigenol2, it was rarely documented outside laboratory settings.

Legality

Legality not written up yet

References

Citations

  1. Further studies on oxygenated tryptamines with LSD-like activity incorporating a chiral pyrrolidine moiety into the side chain. Journal of Medicinal Chemistry (1999). https://doi.org/10.1021/jm990325u12
  2. Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders. Google Patents (2024). https://patents.google.com/patent/WO2024052895A1/en1

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed: this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the 4-HO-MPMI article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.